SciELO - Scientific Electronic Library Online

vol.35 número2Hemocultivos en recién nacidos: optimizando la toma de muestra y su rendimiento índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados




Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google


Revista chilena de infectología

versión impresa ISSN 0716-1018


ROSALES, Ruth et al. The challenge in colistin dosing: Updating available recommendations. Rev. chil. infectol. [online]. 2018, vol.35, n.2, pp.105-116. ISSN 0716-1018.

Polymyxins have been available since the 1960s, however, because of their adverse effects, their use has been reserved for the treatment of infections caused by multiresistant bacteria. The increase in the clinical experience acquired in recent years and the published medical literature have raised doubts about the information provided by the product, indicating the need to update dosage recommendations, pharmacokinetics and pharmacokinetic/pharmacodynamic information (PK/PD). In addition, differences in concentration and dose between the different products of colistin may lead to errors of indication/administration and pose a risk to patients. In 2013, the European Medicines Agency (EMA) commissioned the Committee for Medicinal Products for Human Use (CHPM) to review available data and to make updated recommendations on the use of colistin. This procedure yielded a first report in 2014. This review highlights critical safety and efficacy aspects, reviews the recent pharmacokinetic and stability advances, the available pharmaceutical forms in Chile, providing the schemes currently recommended by health care agencies and experts in the field.

Palabras clave : Colistin; pharmacokinetic; pharmacodynamics; efficacy; safety; Gram negative bacilli; multiresistant.

        · resumen en Español     · texto en Español     · Español ( pdf )